| Primary information |
|---|
| sequence ID | Seq_7475 |
| Peptide sequence | SPLFMGKVVNPTQK |
| CancerPDF_ID | CancerPDF_ID747, CancerPDF_ID1614, CancerPDF_ID1615, CancerPDF_ID2824, CancerPDF_ID2825, CancerPDF_ID9515, CancerPDF_ID9517, |
| PMID | 19795908,21136997,21136997,21136997,21136997,21533267,21533267 |
| Protein Name | Alpha-1-antitrypsin,Alpha-1 protease inhibitor,Alpha-1 protease inhibitor,Alpha-1 protease inhibitor,Alpha-1 protease inhibitor,Alpha-1-antitrypsin,Alpha-1-antitrypsin |
| UniprotKB Entry Name | A1AT_HUMAN,NA,NA,NA,NA,A1AT_HUMAN,A1AT_HUMAN |
| Fluid | Plasma,Serum,Serum,Plasma,Plasma,Serum,Serum |
| M/Z | 515.95,1544.83848,1560.8334,1544.8385,1560.8334,521.27,515.94 |
| Charge | 3,1,1,1,1,3,3 |
| Mass (in Da) | NA,NA,NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS,LC-MS,LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC/MS/MS,LC/MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,Multiple Reaction Monitoring,Multiple Reaction Monitoring |
| Labelled/Label Free | Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | less than 7%,NA,NA,NA,NA,1.49,1.49 |
| CancerPDF_ID | CancerPDF_ID747, CancerPDF_ID1614, CancerPDF_ID1615, CancerPDF_ID2824, CancerPDF_ID2825, CancerPDF_ID9515, CancerPDF_ID9517, |
| p-Value | NA,NA,NA,NA,NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT |
| Length | 14,14,14,14,14,14,14 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Colorectal cancer,Normal,Normal,Lung adenocarcinoma,Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,SwissProt Database,SwissProt Database,SwissProt Database,SwissProt Database,Swissprot Database (57.4),Swissprot Database (57.4) |
| Modification | NA,NA,Oxidation of Met,NA,Oxidation of Met,Oxidation,NA |
| Number of Patients | "40 normal, 26 patients",30 patients and 30 healthy controls,30 patients and 30 healthy controls,27 healthy individuals,27 healthy individuals,62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | NA,Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA,NA,NA,NA,NA,NA |
| Specificity | NA,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | 439314
|